key: cord-0936455-8eytwaaf
authors: Powell, Annabel A; Power, Linda; Westrop, Samantha; McOwat, Kelsey; Campbell, Helen; Simmons, Ruth; Ramsay, Mary E; Brown, Kevin; Ladhani, Shamez N; Amirthalingam, Gayatri
title: Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England
date: 2021-07-15
journal: Euro Surveill
DOI: 10.2807/1560-7917.es.2021.26.28.2100634
sha: 14af0891e9a6e09d6f3353fff7d28c480087d623
doc_id: 936455
cord_uid: 8eytwaaf

Adults receiving heterologous COVID-19 immunisation with mRNA (Comirnaty) or adenoviral-vector (Vaxzevria) vaccines had higher reactogenicity rates and sought medical attention more often after two doses than homologous schedules. Reactogenicity was higher among ≤ 50 than > 50 year-olds, women and those with prior symptomatic/confirmed COVID-19. Adults receiving heterologous schedules on clinical advice after severe first-dose reactions had lower reactogenicity after dose 2 following Vaxzevria/Comirnaty (93.4%; 95% confidence interval: 90.5–98.1 vs 48% (41.0–57.7) but not Comirnaty/Vaxzevria (91.7%; (77.5–98.2 vs 75.0% (57.8–87.9).

Adults receiving heterologous COVID-19 immunisation with mRNA (Comirnaty) or adenoviral-vector (Vaxzevria) vaccines had higher reactogenicity rates and sought medical attention more often after two doses than homologous schedules. Reactogenicity was higher among ≤ 50 than > 50 year-olds, women and those with prior symptomatic/confirmed COVID-19. Adults receiving heterologous schedules on clinical advice after severe first-dose reactions had lower reactogenicity after dose 2 following Vaxzevria/Comirnaty (93.4%; 95% confidence interval: 90.5-98.1 vs 48% (41.0-57.7) but not Comirnaty/Vaxzevria (91.7%; (77.5-98.2 vs 75.0% (57. 8-87.9 ).

Concerns about vaccine-induced thrombosis and thrombocytopenia syndrome (VITTs) following vaccination with (coronavirus disease) COVID-19 adenoviral vector vaccines has led to several countries recommending an mRNA vaccine for the second dose in younger adults who had been given an adenoviral vector vaccine for their first dose [1] [2] [3] [4] . A clinical trial in England (COM-COV) reported that heterologous schedules using mRNA-based Comirnaty (BNT162b2, BioNTech-Pfizer, Mainz, Germany/New York, United States) hereafter referred to as BNT, and adenovirus vector Vaxrevia (ChAdOx1/nCoV-19, AstraZeneca, Cambridge, United Kingdom), hereafter ChAd, COVID-19 vaccines after a 4-week interval were associated with increased reactogenicity after the booster dose compared with their homologous counterparts, although none required hospitalisation [5] .

Here we report on the real-world effects of heterologous prime-boost COVID-19 vaccination following the UK extended schedule of up to 12 weeks between doses.

We used the National Immunisation Management System (NIMS) database to identify adults aged 18-75 years recorded as having received a heterologous prime-boost schedule in England. We identified 26,779 adults with a heterologous schedule between 29 March 2021 and 01 June 2021, initially in London, the South East and East of England but later extended nationally. In addition, 10,000 adults who received a homologous prime-boost schedule on 01 June 2021 in England were identified through NIMS on 08 June 2021 [6] . Of these, 7,484 individuals who were recorded as receiving their second dose in the previous 21 days and had provided a mobile phone number were texted a link to an online survey using SnapSurvey. 1,549 individuals accessed the online survey, 1,397 completed the questionnaire and 1,313 were included in the analysis which gave a response rate of 18.7% (Figure 1 ). Statistical analysis was performed using STATA/SE v.15.1 and graphs created in RStudio [7] . Other reasons for receiving a heterologous schedule included supply issues, individuals requesting a different vaccine, receiving a different vaccine by mistake or other reasons including family history of clotting or recently pregnant. In this cohort, too, reactogenicity was higher in those receiving a heterologous compared with homologous schedules ( Table 3) . . Please note individuals could report more than one reaction therefore totals do not match the sum of the symptoms.

Number Please note individuals could report more than one reaction therefore totals do not match the sum of the symptoms.

Flow diagram of participants with neither previous symptoms of COVID-19 nor confirmed infection who reported severe reactions (Grades 3 or 4) for their second dose of the vaccine by those that reported severe reactions after their first dose and those that reported non-severe reactions (Grades 0-2) after their first dose by vaccination schedule 

Public Health England has legal permission, provided by Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002, to process patient confidential information for national surveillance of communicable diseases and as such, individual patient consent is not required to access records. Individual patient consent was obtained by those who completed the questionnaire.

COVID-19 vaccines have been deployed at scale with great success in many countries, but most of the global population remains unvaccinated [8] . In Europe, most vaccinated individuals have received mRNA or adenoviral-vector vaccines. For two-dose schedules, individuals are recommended to receive the same vaccine brand because of a lack of data on heterologous schedules. For some, however, it may be necessary to offer a different type of vaccine for their second dose if, for example, they experienced severe anaphylaxis after their first dose. Given the global demand for COVID-19 vaccines and potential interruptions in supply, vaccine shortages may lead to policies recommending a heterologous vaccine schedule to provide more rapid protection, especially in the context of new variants, where one dose may provide only partial protection [9] .

Following national implementation of COVID-19 vaccines in England, we found that previously-uninfected individuals who received heterologous prime-boost schedules were 2.4 times (27.8% vs. 11.6%) more likely to report severe reactogenicity, including increased requirement for medical attention, after their second dose than those receiving homologous schedules. These findings were irrespective of the reason for receiving a heterologous schedule. Reactogenicity rates were higher in younger adults, women and after the first dose of ChAd in any schedule. Those experiencing severe reactions after their first dose, irrespective of the vaccine type, were more than twice as likely to experience a severe reaction after the second dose compared to those reporting a no or a mildto-moderate reaction after their first dose (29.7% vs. 13.3%). Our findings suggest that adults who have a severe reaction to their first dose should be advised that their risk of a severe reaction after their second dose will be higher with a heterologous schedule than a homologous schedule. Therefore, completion with the same vaccine brand should be considered unless there is clear evidence of anaphylaxis or other contraindications such as VITTs.

Our study is consistent with existing trial data reporting increased reactogenicity after ChAd prime but not with data reporting increased reactogenicity after BNT/ BNT boost [10, 11] . It is also consistent with the COM-COV study reporting increased reactogenicity following either heterologous schedule using a 4-week interval in healthy individuals [5] . Our real-world data in individuals receiving the UK-recommended 8-12 week extended schedule included a higher proportion of women, under 50 year-olds and at least 10% of participants with prior COVID-19. All these factors may have contributed to the higher proportion of people reporting severe reactions or requiring medical attention. This contrasts with multiple studies in Germany that reported little difference in reactogenicity between homologous and heterologous schedules [12] [13] [14] . While these studies were based on similar extended schedules for heterologous doses, none included a BNT/ ChAd schedule. One study compared reactogenicity after ChAd/BNT with both homologous schedules [12] , while others used BNT/BNT for comparison [13, 14] . A Spanish clinical trial also reported mild reactogenicity overall following an extended ChAd/BNT schedule [15] , but did not have a control arm, instead comparing reactogenicity to non-contemporaneous clinical trial data of homologous ChAd and BNT schedules [10, 11] . Choice of controls, demographics including age, sex and prior infection may account for some of the observed differences.

The strength of our study is the use of real-world data to assess reactogenicity and need for medical attention after different COVID-19 vaccines and schedules. Our findings are, however, only applicable to heterologous immunisation with mRNA and adenoviral vector vaccines. Other potential limitations include recruitment bias towards those with more severe reactions and recall bias because participants completed the questionnaire after their second dose. We also relied on participants reporting COVID-19 symptoms and diagnosis before vaccination. These potential biases would, however, have been equivalent across the different schedules.

Emerging immunogenicity studies indicate robust immune responses after heterologous immunisation in animal models [16] , and increased antibody titres, cellular responses and neutralising activity against variants-of-concern in adults receiving ChAd/BNT [12] [13] [14] . If confirmed in further studies, the benefits of better and potentially longer protection following heterologous schedules will need to be carefully assessed against increased reactogenicity as we have reported here. These findings will also have implications for considerations on the needs of future boosting doses.

Swedish Public Health Agency. Recommendation for a 65-year age limit for AstraZeneca's vaccine remains

Stockholm: Folkhälsomyndigheten

Covid-19: what vaccine strategy for people under 55 who have already received a dose of AstraZeneca?

Denmark continues its vaccine rollout without the COVID-19 vaccine from AstraZeneca. Copenhagen: Danish Health Authority

NACI rapid response: Interchangeability of authorized COVID-19 vaccines. Ottawa: Public Health Agency of Canada

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

COVID-19 Vaccinations. London: NHS England

R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing

Oxford: Our World in Data

SARS-CoV-2 variants of concern and variants under investigation in England. London: Public Health England

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Immunogenicity and reactogenicity of a heterologous COVID-19 prime-boost vaccination compared with homologous vaccine regimens

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

The authors would like to thank all participants who filled out the questionnaire. The authors are also grateful to PHE staff who helped with the study: Corinne Whillock, Teresa Gibbs, Deborah Cohen, Paul Charter, Julie Brough, Adolphe Bukasa, Natalie Mensah, Charlotte Ryan and Molly Viggars.Funding: This surveillance was internally funded by Public Health England and did not receive any specific grant funding from agencies in the public, commercial or not-for-profit sectors.

None declared.

GA, SL, KB and MR contributed to the design of the research, AP, LP, SW, KM, HC and RS contributed to implementation of the study, AP, SL, GA and KB analysed the data and wrote the manuscript with input from all authors.

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.Any supplementary material referenced in the article can be found in the online version.